Zenas BioPharma, Inc.
ZBIONext catalyst
Obexelimab
IgG4-RD accepted by FDA; PDUFA target action date of May 27
Get an email about ZBIO's next catalysts
Track Zenas BioPharma (ZBIO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
FDA PDUFA Date Obexelimab
For IgG4-RD accepted by FDA; PDUFA target action date of May 27. bla filing. Extracted from SEC filing: EXHIBIT 99.1
SourceUpcoming FDA decisions
How ZBIO's past catalysts played out
Market Overview
Stock performance and key metrics
Obexelimab
IgG4 Related Disease
Orelabrutinib
Multiple Sclerosis (MS) Primary Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obexelimab | Phase 3 | IgG4 Related Disease | - | - |
Orelabrutinib | Phase 3 | Multiple Sclerosis (MS) Primary Progressive | - | - |
Frequently asked questions
What is in Zenas BioPharma, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Zenas BioPharma, Inc.'s (ZBIO) pipeline across Phase 3. Its lead program is Obexelimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zenas BioPharma, Inc.'s next FDA catalyst?→
Zenas BioPharma, Inc.'s (ZBIO) next tracked catalyst is a PDUFA date expected May 27, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZBIO biotech catalysts?→
Add ZBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zenas BioPharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.